公开(公告)号：US08709489B2

公开(公告)日：2014-04-29

申请号：US12894983

申请日：2010-09-30

Applicant: Joram Slager ,  Aleksey V. Kurdyumov ,  Dale G. Swan

Inventor： Joram Slager ,  Aleksey V. Kurdyumov ,  Dale G. Swan

IPC: A61K9/16 ,  A61K9/50 ,  A01K25/00 ,  A61K47/00

CPC classification number: A61K9/107 ,  A61K9/0019 ,  A61K9/0024 ,  A61K9/113 ,  A61K9/5036

Abstract: The invention provides emulsion compositions that include a hydrophobic compound and an arylboronic acid. An exemplary emulsion comprises a hydrophobic polymer and a halogenated arylboronic acid. Use of an arylboronic acid provides the emulsion with exceptional stability. The stability provides advantages for the formation of articles formed from the emulsion, including microparticles, as well as other implantable or injectable medical articles having polymeric matrices.

Abstract translation: 本发明提供了包含疏水化合物和芳基硼​​酸的乳液组合物。 示例性的乳液包含疏水性聚合物和卤代芳基硼酸。 使用芳基硼酸提供了非常稳定的乳液。 稳定性为形成由乳液形成的制品提供了优点，包括微粒，以及具有聚合物基质的其它可植入或可注射的医疗制品。

公开(公告)号：US08246576B2

公开(公告)日：2012-08-21

申请号：US12774954

申请日：2010-05-06

Applicant: Joram Slager

Inventor： Joram Slager

IPC: A61M31/00 ,  A61M29/00

CPC classification number: A61M25/10 ,  A61B17/12022 ,  A61B17/12172 ,  A61B17/12177 ,  A61B17/1219 ,  A61B2017/00893 ,  A61F2/82 ,  A61F2250/0067 ,  A61L29/146 ,  A61L29/16 ,  A61L31/146 ,  A61L31/16 ,  A61L2300/622 ,  A61M29/02 ,  A61M2025/105

Abstract: Described herein is a medical device that has a collapsed configuration and an expanded configuration wherein one or more polymeric network layers are applied to the substrate and microparticles embedded in the polymeric network. The polymeric network layer or layers is/are configured to retain the microparticles when the device is in a collapsed configuration and to release the microparticles when the device is in an expanded configuration. Methods for delivering a therapeutic agent using the device and making the device are also disclosed.

Abstract translation: 本文描述的是具有折叠构型和扩展构型的医疗装置，其中将一个或多个聚合物网络层施加到基底和嵌入聚合物网络中的微粒。 聚合物网络层被配置为当装置处于折叠构型时保持微粒，并且当装置处于扩张构型时释放微粒。 还公开了使用该装置递送治疗剂并制备该装置的方法。

公开(公告)号：US20110159098A1

公开(公告)日：2011-06-30

申请号：US12968365

申请日：2010-12-15

Applicant: Joram Slager

Inventor： Joram Slager

IPC: A61K31/713 ,  A61K39/395 ,  A61K9/00 ,  A61K47/48 ,  A61P9/00 ,  A61P27/02 ,  A61P15/00 ,  A61P11/00 ,  A61P25/00 ,  C12N5/071

CPC classification number: A61K31/713 ,  A61K9/0019 ,  A61K9/127 ,  A61K9/146 ,  C07K16/00 ,  C07K2317/55 ,  C12N15/111 ,  C12N15/87 ,  C12N2320/32

Abstract: Compositions and methods for delivering nucleic acid, including siRNA, to a target cell are provided. In one embodiment, the composition includes the nucleic acid and a stabilizing protein. In another embodiment, the nucleic acid is complexed with a carrier, for example, a peptide carrier. In yet another embodiment, the nucleic acid combined with a protein which is cross-linked to form a proteinaceous controlled release matrix. Methods for making the compositions are also described.

Abstract translation: 提供了将核酸（包括siRNA）递送至靶细胞的组合物和方法。 在一个实施方案中，组合物包括核酸和稳定蛋白。 在另一个实施方案中，核酸与载体例如肽载体复合。 在另一个实施方案中，核酸与交联的蛋白质组合以形成蛋白质控制释放基质。 还描述了制备组合物的方法。

公开(公告)号：US20100260850A1

公开(公告)日：2010-10-14

申请号：US12756493

申请日：2010-04-08

Applicant: Joram Slager

Inventor： Joram Slager

IPC: A61K9/14 ,  A61K9/00 ,  A61K31/7088 ,  A61P43/00 ,  A61K31/7105

CPC classification number: A61K9/1641 ,  A61K9/1647 ,  A61K9/1658 ,  A61K9/7007 ,  A61K47/6455 ,  A61K48/0041 ,  C12N15/111 ,  C12N2310/14 ,  C12N2320/32

Abstract: Embodiments of the invention include devices and methods for the delivery of nucleic acids. In an embodiment the invention includes a controlled release device including a polymeric matrix and a nucleic acid delivery construct disposed within the polymeric matrix. The nucleic acid delivery construct can include a nucleic acid molecule and a peptide molecule. The nucleic acid delivery construct can be configured to exhibit elution properties of a peptide from the polymeric matrix. The polymeric matrix can be configured to elute the nucleic acid delivery construct. Other embodiments are included herein.

Abstract translation: 本发明的实施方案包括用于递送核酸的装置和方法。 在一个实施方案中，本发明包括包含聚合物基质和设置在聚合物基质内的核酸递送构建体的控制释放装置。 核酸递送构建体可以包括核酸分子和肽分子。 核酸递送构建体可以被配置为显示来自聚合物基质的肽的洗脱性质。 聚合物基质可以被配置为洗脱核酸递送构建体。 本文还包括其它实施例。

公开(公告)号：US20090280181A1

公开(公告)日：2009-11-12

申请号：US12437287

申请日：2009-05-07

Applicant: Joram Slager

Inventor： Joram Slager

IPC: A61K9/14 ,  A61K31/7052 ,  A61P43/00

CPC classification number: A61K9/1641 ,  A61K9/0024 ,  A61K9/1623 ,  A61K9/1652 ,  A61K9/1658 ,  A61K47/543 ,  A61K47/58 ,  A61K47/59 ,  A61K47/593 ,  A61K47/60 ,  A61K47/61 ,  A61K47/6921 ,  A61K47/6923 ,  A61K47/6957 ,  A61K48/00 ,  C12N15/87

Abstract: Embodiments of the invention include particles with nucleic acid complexes, medical devices including the same and related methods. In an embodiment, the invention can include a method of making a medical device. The method can include contacting nucleic acids with cationic carrier agents to form nucleic acid complexes, adsorbing the nucleic acid complexes to porous particles to form nucleic acid complex containing particles, mixing the nucleic acid complex containing particles with a polymer solution to form a coating mixture, and applying the coating mixture to a substrate. In an embodiment, the method can include contacting nucleic acids with cationic carrier agents to form nucleic acid complexes, combining the nucleic acid complexes with a material to form nucleic acid complex containing particles in situ, mixing the nucleic acid complex particles with a polymer solution to form a coating mixture, and applying the coating mixture to a substrate. In an embodiment, the invention can include an implantable medical device including a substrate, an elution control matrix disposed on the substrate; a plurality of particles disposed within the elution control matrix, and a plurality of nucleic acid complexes disposed within the particles, the nucleic acid complexes comprising a nucleic acid and a cationic carrier agent. Other embodiments are included herein.

Abstract translation: 本发明的实施方案包括具有核酸复合物的颗粒，包括相同方法的医疗装置。 在一个实施例中，本发明可以包括制造医疗装置的方法。 该方法可以包括使核酸与阳离子载体接触以形成核酸复合物，将核酸复合物吸附到多孔颗粒上以形成含有核酸复合物的颗粒，将含有核酸复合物的颗粒与聚合物溶液混合以形成涂层混合物， 并将涂覆混合物施加到基底上。 在一个实施方案中，该方法可以包括使核酸与阳离子载体试剂接触以形成核酸复合物，将核酸复合物与材料组合以形成原位含有颗粒的核酸复合物，将核酸复合物颗粒与聚合物溶液混合 形成涂料混合物，并将涂料混合物施加到基材上。 在一个实施例中，本发明可以包括可植入医疗装置，其包括基底，设置在基底上的洗脱控制矩阵; 布置在洗脱控制基质内的多个颗粒，以及设置在颗粒内的多个核酸复合物，所述核酸复合物包含核酸和阳离子载体试剂。 本文还包括其它实施例。

公开(公告)号：US20090022805A1

公开(公告)日：2009-01-22

申请号：US12215508

申请日：2008-06-27

Applicant: Joram Slager ,  Michael D. New ,  John V. Wall ,  Michael J. Burkstrand ,  Stephen J. Chudzik ,  Pamela J. Reed

Inventor： Joram Slager ,  Michael D. New ,  John V. Wall ,  Michael J. Burkstrand ,  Stephen J. Chudzik ,  Pamela J. Reed

IPC: A61K9/14 ,  A61P43/00

CPC classification number: A61K9/5036 ,  C07K16/42 ,  C07K2317/55

Abstract: The invention provides polypeptide microparticles having control release features, particular methods for the preparation of such microparticles, and drug delivery systems that include polypeptide microparticles.

Abstract translation: 本发明提供了具有控制释放特征的多肽微粒，用于制备这种微粒的具体方法以及包括多肽微粒的药物递送系统。

公开(公告)号：US20080213334A1

公开(公告)日：2008-09-04

申请号：US11863545

申请日：2007-09-28

Applicant: Nathan A. Lockwood ,  Joram Slager ,  John V. Wall ,  Peter H. Duquette

Inventor： Nathan A. Lockwood ,  Joram Slager ,  John V. Wall ,  Peter H. Duquette

IPC: A61K9/00 ,  A61K47/30 ,  A61K38/02 ,  B05D1/34 ,  A61K38/16 ,  A61K31/7052

CPC classification number: A61L31/16 ,  A61L31/145 ,  A61L2300/606 ,  C08J7/047 ,  C08L25/18 ,  C09D105/08 ,  C09D105/10 ,  C09D125/18 ,  C09D139/02 ,  C09D189/00 ,  C08L2666/04

Abstract: The invention provides polyelectrolyte hydrogels, blends, and multilayers for the controlled release of bioactive agents from implantable medical devices coated with or containing such media.

Abstract translation: 本发明提供了聚电解质水凝胶，共混物和多层，用于由可涂覆或含有这种介质的可植入医疗装置控制释放生物活性剂。

公开(公告)号：US20080038354A1

公开(公告)日：2008-02-14

申请号：US11824340

申请日：2007-06-28

Applicant: Joram Slager ,  Aron Anderson

Inventor： Joram Slager ,  Aron Anderson

IPC: A61K9/00 ,  A61K38/00 ,  A61K39/395

CPC classification number: A61L27/48 ,  A61L27/54 ,  A61L31/129 ,  A61L31/16 ,  A61L2300/252 ,  A61L2300/256 ,  A61L2300/622 ,  C08L71/02 ,  C08L31/04 ,  C08L33/10

Abstract: The present invention is directed to polymeric matrices for the controlled release of a hydrophilic bioactive agent. Generally, the elution control matrix includes a polymeric matrix having a first polymer and a plurality of microparticles that include the hydrophilic bioactive agent. In one embodiment, the matrix includes a polymer comprising hydrophilic and hydrophobic portions. In another embodiment, the microparticles include a crosslinked hydrophilic polymer.

Abstract translation: 本发明涉及用于控制释放亲水生物活性剂的聚合物基质。 通常，洗脱控制基质包括具有第一聚合物和包含亲水生物活性剂的多个微粒的聚合物基质。 在一个实施方案中，基质包括包含亲水和疏水部分的聚合物。 在另一个实施方案中，微粒包括交联的亲水性聚合物。

公开(公告)号：US08901092B2

公开(公告)日：2014-12-02

申请号：US13335724

申请日：2011-12-22

Applicant: Joram Slager

Inventor： Joram Slager

IPC: A01N43/04 ,  A61K31/70 ,  A61K31/713 ,  C08B37/00 ,  A61K31/7088 ,  C08L5/00 ,  C12N15/87 ,  A61K48/00

CPC classification number: A61K31/7088 ,  A61K31/713 ,  A61K48/00 ,  C08B37/0009 ,  C08L5/00 ,  C12N15/87

Abstract: Embodiments of the invention include functionalized polysaccharides and compositions and structures including the same. In an embodiment, the invention includes an active agent delivery composition including a polysaccharide functionalized with a coupling group, wherein the polysaccharide lacks charged groups at a pH of between 6 and 8; and a complex comprising a nucleic acid and a transfection agent. In an embodiment, the invention includes an active agent delivery structure including a matrix comprising a polysaccharide covalently cross-linked through the residue of a coupling group on the polysaccharide, the polysaccharide lacking charged groups at a pH of between 6 and 8; and a nucleic acid delivery complex disposed within the active agent delivery structure. In an embodiment, the invention includes a material for medical applications including glycogen functionalized with coupling groups at a degree of substitution of between about 0.01 and 0.5. Other embodiments are also included herein.

Abstract translation: 本发明的实施方案包括官能化多糖及包含其的组合物和结构。 在一个实施方案中，本发明包括活性剂递送组合物，其包含用偶联基团官能化的多糖，其中所述多糖在6至8的pH下缺少带电基团; 和包含核酸和转染剂的复合物。 在一个实施方案中，本发明包括活性剂递送结构，所述活性剂递送结构包括通过多糖上的偶联基团的残基共价交联的多糖的基质，pH在6至8之间缺少带电基团的多糖; 以及设置在活性剂递送结构内的核酸递送复合物。 在一个实施方案中，本发明包括用于医疗应用的材料，包括以约0.01至0.5的取代度的偶联基团官能化的糖原。 本文还包括其它实施例。

公开(公告)号：US20110319473A1

公开(公告)日：2011-12-29

申请号：US13171171

申请日：2011-06-28

Applicant: Joseph Schmidt McGonigle ,  Joram Slager

Inventor： Joseph Schmidt McGonigle ,  Joram Slager

IPC: A61K31/713 ,  C07H21/02

CPC classification number: A61K9/19 ,  A61K9/1272 ,  A61K9/1647 ,  A61K9/1652 ,  A61K47/36 ,  A61K48/0041 ,  C12N15/88

Abstract: Embodiments of the invention include devices and methods for delivery of nucleic acids as active agents. Embodiments of the invention include devices and methods for delivery of nucleic acids as active agents. In an embodiment, an article for delivering an active agent is included. The article can include a dehydrated complex including a nucleic acid, a transfection agent, and a saccharide protectant. The nucleic acid and transfection agent can form a liposome or a lipoplex. The dehydrated complex can be disposed within a polymeric matrix. The dehydrated complex can be disposed within a microparticle. Other embodiments are also included herein.

Abstract translation: 本发明的实施方案包括用于递送核酸作为活性剂的装置和方法。 本发明的实施方案包括用于递送核酸作为活性剂的装置和方法。 在一个实施例中，包括用于递送活性剂的物品。 该制品可以包括脱水复合物，其包括核酸，转染剂和糖类保护剂。 核酸和转染剂可形成脂质体或脂质体。 脱水复合物可以设置在聚合物基质内。 脱水复合物可以设置在微粒内。 本文还包括其它实施例。